Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A D Schimmer

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Current Cancer Drug Targets|January 21, 2011
Clioquinol - a novel copper-dependent and independent proteasome inhibitorA D Schimmer
Oncogene|June 18, 2013
Mitochondrial matrix proteases as novel therapeutic targets in malignancyC A Goard, A D Schimmer
Cell Death and Differentiation|December 3, 2005
Targeting XIAP for the treatment of malignancyA D Schimmer, S Dalili, R A Batey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 13, 2001
Male sexual function after autologous blood or marrow transplantationA D Schimmer, V Ali, A K Stewart, et al.
International Journal of Laboratory Hematology|March 21, 2017
Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemiaR J Guo, E G Atenafu, A D Schimmer, et al.
Journal of Clinical Pharmacy and Therapeutics|March 4, 2011
The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancyS J Weir, L Patton, K Castle, et al.
Leukemia & Lymphoma|November 9, 2001
BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potentialA D Schimmer, D W Hedley, N A Pham, et al.
Oncogene|March 29, 2011
New model systems provide insights into Myc-induced transformationA R Wasylishen, A Stojanova, S Oliveri, et al.
Leukemia|January 24, 2017
Biological and clinical consequences of NPM1 mutations in AMLE M Heath, S M Chan, M D Minden, et al.
Bone Marrow Transplantation|September 26, 2001
Decreased bone mineral density is common after autologous blood or marrow transplantationA D Schimmer, K Mah, L Bordeleau, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Current Cancer Drug Targets|January 21, 2011
Clioquinol - a novel copper-dependent and independent proteasome inhibitorA D Schimmer
Oncogene|June 18, 2013
Mitochondrial matrix proteases as novel therapeutic targets in malignancyC A Goard, A D Schimmer
Cell Death and Differentiation|December 3, 2005
Targeting XIAP for the treatment of malignancyA D Schimmer, S Dalili, R A Batey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 13, 2001
Male sexual function after autologous blood or marrow transplantationA D Schimmer, V Ali, A K Stewart, et al.
International Journal of Laboratory Hematology|March 21, 2017
Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemiaR J Guo, E G Atenafu, A D Schimmer, et al.
Journal of Clinical Pharmacy and Therapeutics|March 4, 2011
The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancyS J Weir, L Patton, K Castle, et al.
Leukemia & Lymphoma|November 9, 2001
BAD induces apoptosis in cells over-expressing Bcl-2 or Bcl-xL without loss of mitochondrial membrane potentialA D Schimmer, D W Hedley, N A Pham, et al.
Oncogene|March 29, 2011
New model systems provide insights into Myc-induced transformationA R Wasylishen, A Stojanova, S Oliveri, et al.
Leukemia|January 24, 2017
Biological and clinical consequences of NPM1 mutations in AMLE M Heath, S M Chan, M D Minden, et al.
Bone Marrow Transplantation|September 26, 2001
Decreased bone mineral density is common after autologous blood or marrow transplantationA D Schimmer, K Mah, L Bordeleau, et al.
Pageof 3